Vibraint ApS
Vibraint is a preclinical contract research organization providing quantitative whole-brain mouse imaging through its LS-Journey™ platform, which combines whole-brain immunolabelling, light sheet fluorescence microscopy, and AI-assisted image analysis. The platform captures every labelled cell across 800+ anatomical regions simultaneously, delivering interactive 2D and 3D datasets via the CNS-Voyager™ viewer for unbiased neuroscience research.
- Biotechnology
- Drug Discovery & Therapeutics
- Data & Analytics
- Artificial Intelligence
- Hardware
- Healthcare Technology
- Software Only
Funding
Raised to date
$2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 1 round
$2M · Seed
Announced Feb 2026
Disclosed cumulative: $2M
Founders
Founder details are not available yet.
Product
Problem
Traditional immunohistochemistry relies on physically sectioning the brain into thin slices, limiting analysis to 10–15 pre-selected regions and introducing unavoidable sampling bias. This approach destroys the brain's 3D spatial context, requires weeks of manual cell counting, and produces observer-dependent results that miss potentially important biological effects in unexamined regions.
Solution
Vibraint provides an end-to-end preclinical imaging platform called LS-Journey™ that transforms intact mouse brains into quantitative 3D datasets. The platform combines whole-brain immunolabelling using optical tissue clearing and 3D immunohistochemistry, light sheet fluorescence microscopy for cellular-resolution acquisition, and AI-assisted image analysis with deep learning cell detection and atlas registration. This integrated workflow captures every labelled cell across 800+ anatomical regions simultaneously in a single unbiased experiment, preserving the brain's 3D architecture. The modular design allows researchers to use individual steps—such as tissue clearing, imaging, or analysis—or the complete pipeline, with data delivered through the CNS-Voyager™ interactive platform for exploration and sharing.
Target Audience
Primary customers are pharmaceutical companies and academic neuroscience researchers conducting preclinical studies in drug discovery, target validation, and disease mechanism research that require unbiased, quantitative whole-brain data.
Features
- Whole-brain immunolabelling using iDISCO+ tissue clearing that supports markers including c-Fos, CD31, aSMA, pSTAT3, GFP, RFP, and custom antibodies, with primary antibody diffusion over 7–8 days at 37°C
- Light sheet fluorescence microscopy generating ~1 TB of raw image data per brain at cellular resolution
- AI-assisted cell detection and signal quantification with CCF atlas registration covering 800+ brain regions
- Modular platform design allowing independent use of immunolabelling, microscopy, or analysis modules, with standalone services for imaging externally labelled samples or analyzing raw user data
- Interactive 2D and 3D data viewing through the CNS-Voyager™ platform with scrollable brain volumes and region-specific lookup
- Study and regulatory report generation suitable for FDA/EMA submissions